Syndromic surveillance is increasingly used to signal unusual illness events. To validate data-source selection, we retrospectively investigated the extent to which 6 respiratory syndromes (based on different medical registries) reflected respiratory pathogen activity. These syndromes showed higher levels in winter, which corresponded with higher laboratory counts of *Streptococcus pneumoniae*, respiratory syncytial virus, and influenza virus. Multiple linear regression models indicated that most syndrome variations (up to 86%) can be explained by counts of respiratory pathogens. Absenteeism and pharmacy syndromes might reflect nonrespiratory conditions as well. We also observed systematic syndrome elevations in the fall, which were unexplained by pathogen counts but likely reflected rhinovirus activity. Earliest syndrome elevations were observed in absenteeism data, followed by hospital data (+1 week), pharmacy/general practitioner consultations (+2 weeks), and deaths/laboratory submissions (test requests) (+3 weeks). We conclude that these syndromes can be used for respiratory syndromic surveillance, since they reflect patterns in respiratory pathogen activity.

Early warning surveillance for emerging infectious disease has become a priority in public health policy since the anthrax attacks in 2001, the epidemic of severe acute respiratory syndrome in 2003, and the renewed attention on possible influenza pandemics. As a result, new surveillance systems for earlier detection of emerging infectious diseases have been implemented. These systems, often labeled “syndromic surveillance,” benefit from the increasing timeliness, scope, and diversity of health-related registries (1–6). Such alternative surveillance uses symptoms or clinical diagnoses such as “shortness of breath” or “pneumonia” as early indicators for infectious disease. This approach not only allows clinical syndromes to be monitored before laboratory diagnoses, but also allows disease to be detected for which no additional diagnostics were requested or available (including activity of emerging pathogens). Our study assessed the suitability of different types of healthcare data for syndromic surveillance of respiratory disease.

We assumed that syndrome data—to be suitable for early detection of an emerging respiratory disease—should reflect patterns in common respiratory infectious diseases (7–10). Therefore, we investigated the extent to which time-series of respiratory pathogens (counts per week in existing laboratory registries) were reflected in respiratory syndrome time-series as recorded in 6 medical registries in the Netherlands. We also investigated syndrome variations that could not be explained by pathogen counts. As an indication for syndrome timeliness, we investigated the delays between the syndrome and pathogen time-series.

Methods

Syndrome Data Collection and Case Definitions

We defined syndrome data as data in health-related registries that reflect infectious disease activity without identifying causative pathogen(s) or focusing on pathogen-specific symptoms (such as routine surveillance data for influenza-like illness [11] or surveillance of acute flaccid paralysis for polio [12]).

Registries for syndrome data were included if they met the following criteria: 1) registration on a daily basis; 2) availability of postal code, age, and sex; 3) availability
of retrospective data (≥2 years); and 4) (potential) real-time data availability.

Six registries were selected (Table 1) that collected data on work absenteeism, general practice (GP) consultations, prescription medications dispensed by pharmacies, diagnostic test requests (laboratory submissions) \( (13) \), hospital diagnoses, and deaths. In all registries, data were available for all or a substantial part of 1999–2004. For the GP, hospital, and mortality registry, definition of a general respiratory syndrome was guided by the case definitions and codes found in the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM), as selected by the Centers for Disease Control and Prevention (Atlanta, GA, USA) (www.bt.cdc.gov/surveillance/syndromedef). For the laboratory submissions and the pharmacy syndrome, we selected all data that experts considered indicative of respiratory infectious disease (for detailed syndrome definitions, see online Technical Appendix, available from www.cdc.gov/EID/content/14/6/917-Techapp.pdf).

### Respiratory Pathogen Counts

As a reference for the syndrome data, we included specific pathogen counts for 1999–2004 from the following sources: 1) Weekly Sentinel Surveillance System of the Dutch Working Group on Clinical Virology (which covers 38%–73% of the population of the Netherlands \( [14] \) for routine laboratory surveillance of respiratory syncytial virus [RSV], influenza A virus, influenza B virus, rhinovirus, *Mycoplasma pneumoniae*, parainfluenza virus, enterovirus, and adenovirus); 2) 6 regional public health laboratories for...

---

**Table 1. Registries from which syndrome data were obtained, the Netherlands, 1999–2004**

| Data type                  | Period          | % Coverage† | Respiratory syndrome definitions‡ | Analyzed data                                                                 | International code system | Registry                      |
|----------------------------|-----------------|-------------|----------------------------------|------------------------------------------------------------------------------|--------------------------|-------------------------------|
| Absenteeism                | 2002–2003       | 80§         | Reported sick employees; no further medical information | Sick leave reports of employees                                               | –                        | Statistics Netherlands (CBS), www.cbs.nl |
| General practice consultations | 2001–2004       | 1–2         | Symptoms and diagnoses indicating respiratory infectious disease | Symptoms and diagnoses recorded in practice or telephone consultations and in home visits | ICPC                      | Netherlands Information Network of General Practice (LINH), www.nivel.nl/linh |
| Pharmacy dispensations     | 2001–2003       | 85          | Prescribed medications indicative for respiratory infectious disease | Prescription medications dispensed in Dutch pharmacies, coded according to the WHO ATC classification | ATC                      | Foundation for Pharmaceutical Statistics, http://www.sfk.nl |
| Hospitalization            | 1999–2004       | 99          | General respiratory symptoms/diagnoses; specific respiratory biologic agent diagnoses | Discharge and secondary diagnoses, date of hospitalization                     | ICD-9-CM                 | Dutch National Medical Register (LMR) |
| Laboratory submissions¶    | 2001–2004 (1999–2000 excluded due to unstable coverage) | 16          | All submissions for microbiologic diagnostic tests on respiratory materials; all submissions for serologic testing on known specific respiratory pathogens; all submissions for *Legionella* or *Streptococcus pneumoniae* antigen tests on urine | Laboratory submission requests for diagnostic testing | –                        | National Infectious Diseases Information System (ISIS) \( (13) \) |
| Mortality                  | 1999–2004       | 100         | General respiratory symptoms/diagnoses; specific respiratory biologic agent diagnoses | Date of death, primary cause of death, complicating factors, other additional causes of death | ICD-10                   | CBS                           |

*ICPC, International Classification of Primary Care; WHO, World Health Organization; ATC, Anatomic Therapeutic Chemical Classification System; ICD-9-CM, International Classification of Diseases, 9th revision, Clinical Modification; ICD-10, International Classification of Diseases, 10th revision.†Percentage of total population, 16.3 million.‡For detailed syndrome definitions and codes, see online Technical Appendix, available from www.cdc.gov/EID/content/14/6/917-Techapp.pdf.§Percentage of working population, 8 million.¶Diagnostic test requests with both negative and positive results.
respiratory disease–related counts of Streptococcus pneumoniae (data in 2003–2004 were interpolated for 2 laboratories during short periods of missing data; total coverage 24%); and 3) national mandatory notifications of pertussis. The networks for respiratory pathogen counts are other networks than the earlier described laboratory submissions network for syndrome data.

Data Analysis and Descriptive Statistics

Data were aggregated by week and analyzed by using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). For the GP, pharmacy, and laboratory submissions registries, we expressed the respiratory counts as a percentage of total weekly counts to adjust for the influence of holidays and, for laboratory submissions, changes in the number of included laboratories over time. By looking at the graphs, we explored the relationship between the time-series of respiratory pathogens and syndromes and calculated Pearson correlation coefficients.

Linear Regression Models

To investigate whether the respiratory syndromes reflect patterns in respiratory pathogen counts, we constructed multiple linear regression models. These models estimated respiratory syndrome levels at a certain time with, as explanatory variables, the lagged (range of –5 to +5 weeks) pathogen counts as explanatory variables. We used linear regression of the untransformed syndrome to estimate the additive contributions of individual pathogens to the total estimated syndrome. We assumed a constant syndrome level attributable to factors other than the respiratory pathogens and constant scaling factors for each of the lagged pathogens. A forward stepwise regression approach was used, each step selecting the lagged pathogen that contributed most to Akaike’s information criterion of model fit (15). Each pathogen entered the model only once and only if it contributed significantly (p<0.05). Negative associations (e.g., between enteroviruses, which peak in summer, vs. respiratory syndromes, which peak in winter) were excluded to avoid noncausal effects.

To discriminate between primary and secondary infections by S. pneumoniae (as a complication of respiratory virus infection) (16–19), we used the residuals from regressing S. pneumoniae counts on other pathogens as the variable for S. pneumoniae (instead of its counts) for all the earlier described models for respiratory syndromes.

We checked for autocorrelation in the residuals of the models with hierarchical time-series models (using SPLUS 6.2) (20,21). We calculated R² values to estimate to what extent respiratory pathogen counts explain variations in syndromes. To explore to what extent seasonal variation could be a confounder, we also calculated R² values of the models after adding seasonal variables (sine and cosine terms) and R² values for seasonal terms alone. We also investigated the pathogen-specific effects in the models, by calculating the standardized parameter estimates before and after adding seasonal terms.

The models were used to estimate the expected syndrome level with 95% upper confidence limits (UCLs). We considered distinct syndrome elevations that exceeded the UCLs, as unexplained by the models (for model details, see online Technical Appendix).

Timeliness

We investigated the timeliness of the registry syndromes in 2 ways: 1) as a measure of differences in timeliness between registries, we evaluated the time delays of the syndromes relative to each other by calculating for each of the syndromes the time lag that maximized Pearson correlation coefficient with the hospital registry (as a reference); 2) by estimating the time delays between each of the syndromes and the lagged pathogens included in its regression model.

Results

Data Exploration and Descriptive Statistics

Respiratory syndrome time series were plotted for all registries (Figure 1). The Christmas and New Year holidays coincided with peaks and dips in the pharmacy and absenteeism syndromes (not shown). Because these results were probably artifacts, we smoothed these yearly peaks and dips and censored them in the analyses performed on the absenteeism registry, in which they had a strong influence on outcomes. For all registries, the respiratory syndromes demonstrated higher levels of activity in winter, which overlapped or coincided roughly with the seasonal peaks of influenza A, influenza B, RSV, and (albeit less pronounced) S. pneumoniae laboratory counts (Figure 1). Infections with parainfluenza virus, M. pneumoniae, adenovirus, and rhinovirus were detected slightly more frequently during winter (data not shown). Bordetella pertussis and enterovirus showed seasonal peaks only in summer (data not shown).

The seasonal peaks in laboratory counts of influenza A, influenza B, and RSV corresponded with peaks in the GP, pharmacy, and hospital syndromes. Other syndromes did have less obvious correspondence. Each year, around October, the respiratory syndrome showed a peak in the GP (2001–2004), pharmacy (2001–2003), and absenteeism (2002–2003) registries (Figure 1, panels A–C) that was observed neither for the other registries nor in any of the laboratory pathogens.

We calculated Pearson correlation coefficients between the different unlagged time series of respiratory pathogens and syndromes (Table 2). Syndrome time series in all reg-
RESEARCH

istries correlated strongly with *S. pneumoniae* (unadjusted total counts). The hospital, GP, pharmacy, and laboratory submissions data strongly correlated with RSV and influenza A counts (Table 2). Mortality data correlated strongly with influenza A (*r* = 0.65) and influenza B (*r* = 0.50) infections. The highest correlations between pathogen time series were between *S. pneumoniae* and the other pathogens (up to 0.51 with influenza A, Table 3).

**Linear Regression Models**

Table 4 presents, for each registry, the time lag (in weeks) that maximized the model fit of regressing syndrome on pathogens. For the GP, hospital, mortality, and pharmacy data, the respiratory pathogens explained the syndrome variation very well (78%–86%). Variations in the absenteeism syndrome could be explained for 68% by variations in the pathogen counts. Although the laboratory submissions syndrome had the lowest explained variance, still 61% of the variations in this syndrome were explained by variations in pathogen counts. Hierarchical time-series models did not show significant autocorrelation in the residuals of the models with pathogen counts as explanatory variables (20,21).

When seasonal terms were added to the model, the variations in the mortality syndrome were just as well ex-

---

**Figure 1.** Respiratory syndrome time series and laboratory pathogen counts in the Netherlands. Respiratory syndromes were defined for the 6 registries defined in Table 1: A) absenteeism, B) general practice (GP) consultations, C) pharmacy, D) laboratory submissions, E) hospitalizations, and F) mortality counts. Pathogens plotted were respiratory syncytial virus (RSV), influenza A, influenza B, and *Streptococcus pneumoniae* [1999–2004 or part of this period, panels A–C]. Recurrent unexplained syndrome elevations in October are circled. Pathogen counts are daily counts of pathogens found in laboratory surveillance.
plained as by the model with only pathogen counts (Table 5; \(R^2\) remains 78%), while by the model with only seasonal terms, the explained variance was much lower (only 52%, Table 5). For the hospitalizations, laboratory submissions, and GP data, only slightly more syndrome variation was explained by adding seasonal terms. With only seasonal terms, the explained variance for these syndromes was clearly lower than with only pathogens in the models (8%-11% lower, Table 5). However, for the absenteeism data, and, to a lesser extent, the pharmacy data, the model with both pathogen and seasonal terms clearly explained more syndrome variations (Table 5, absenteeism 68% vs. 80%; pharmacy 80% vs. 87%). Furthermore, for the absenteeism data, the model with only seasonal terms had an even higher \(R^2\) than the model with only pathogens, whereas for the pharmacy data, the \(R^2\) with only seasonal terms was only slightly lower (3%, Table 5).

Table 6 shows that for mortality, hospitalizations, laboratory submissions, and GP data, the pathogens with the highest effect clearly were RSV, influenza A, and influenza B, with no or only modest decline in standardized parameter estimates after adding seasonal terms. For the GP and hospital data, some pathogens became insignificant after seasonal terms were added (GP: rhinovirus and adenovirus; hospital: parainfluenza virus). For the pharmacy data, half of all pathogen variables became insignificant after seasonal terms were added, whereas for the absenteeism data, almost all pathogens became insignificant (Table 6).

Several syndrome observations exceeded the 95% UCLs of the models (0–10/registry/year), which indicates that those syndrome observations deviated strongly from model predictions. The recurrent elevation in October of the absenteeism, GP, and pharmacy syndrome several times exceeded the UCLs (October 2001: pharmacy and GP; 2002: absenteeism; 2003: GP, absenteeism; not shown), which indicated that the model could not explain these elevations.

### Timeliness

In Figure 2, for each registry, the difference in timeliness with the hospital registry is indicated by the lag that maximizes \(R^2\). The absenteeism syndrome (green line) preceded the hospital syndrome by 1 week, followed by the GP-based and prescription-based syndromes at +1 week and the syndrome based on mortality and laboratory sub-

| Pathogen              | Hospital | GP | Mortality | Pharmacy | Laboratory submissions | Absenteeism |
|-----------------------|----------|----|-----------|----------|------------------------|-------------|
| RSV                   | 0.74     | 0.67 | 0.41      | 0.58     | 0.53                   | 0.47        |
| Influenza A           | 0.57     | 0.61 | 0.65      | 0.60     | 0.47                   | 0.35        |
| Influenza B           | 0.31     | 0.39 | 0.50      | 0.42     | 0.34                   | 0.33        |
| *Streptococcus pneumoniae* | 0.73   | 0.71 | 0.56      | 0.75     | 0.58                   | 0.69        |
| Rhinovirus            | 0.33     | 0.34 | 0.33      | 0.33     | NS                     | 0.35        |
| Parainfluenza         | 0.20     | NS  | NS        | NS       | NS                     | NS          |
| Adenovirus            | 0.37     | 0.35 | 0.33      | 0.36     | NS                     | 0.34        |
| Enterovirus           | −0.65    | −0.66| −0.59     | −0.61    | −0.57                  | −0.51       |
| *Mycoplasma pneumoniae*   | 0.13   | 0.27 | 0.25      | 0.39     | 0.32                   | 0.26        |
| Bordetella pertussis  | NS       | NS  | NS        | NS       | NS                     | NS          |

Table 2. Pearson correlation coefficients between time series of syndromes and laboratory pathogen counts, the Netherlands, 1999–2004†

| Pathogen              | S. pneumoniae | RSV | Influenza A | Influenza B | RV | PIV | Adenovirus | Enterovirus | Mycoplasma pneumoniae | Bordetella pertussis |
|-----------------------|---------------|-----|-------------|-------------|----|-----|------------|-------------|-----------------------|---------------------|
| *S. pneumoniae*       | 1.00          | 0.35| 0.51        | 0.36        | NS | 0.32| 0.32       | −0.44       | 0.21                  | −0.31               |
| RSV                   | 1.00          | 0.23| 0.30        | 0.13        | 0.21| −0.30| 0.19       | NS          | NS                   |
| Influenza A           | 1.00          | 0.36| NS          | 0.12        | 0.24| −0.39| 0.16       | −0.25       |
| Influenza B           | 1.00          | NS  | NS          | NS          | −0.30| 0.25| 0.21       | NS          |
| RV                    | 1.00          | NS  | 0.21        | NS          | NS | NS   | NS         | NS          |
| PIV                   | 1.00          | NS  | −0.19       | NS          | NS | NS   | NS         | NS          |
| Adenovirus            | 1.00          | −0.21| NS          | NS          | −0.14|     | NS         | NS          |
| Enterovirus           | 1.00          | −0.15| 0.21        | NS          |     |     | NS         | NS          |
| *M. pneumoniae*       | 1.00          |     | NS          |             |     |     |            |             |
| B. pertussis          | 1.00          |     |             |             |     |     |            |             |

*S. pneumoniae, Streptococcus pneumoniae; RSV, respiratory syncytial virus; RV, rhinovirus; PIV, parainfluenza virus; NS, nonsignificant. Correlations >0.50 in boldface; p value >0.05.

†Unlagged.
mission data at +2 weeks after the hospital syndrome (projected on x-axis, Figure 2).

The differences in timeliness between the syndromes and the pathogen surveillance data were reflected by the regression models relating the syndromes to the (positive or negative) lagged pathogens (Table 4). Influenza A and influenza B had lags of 0–5 weeks, which suggests that the registry-syndromes were 0–5 weeks ahead of laboratory counts for these infections. Fluctuations in the time series of respiratory hospitalizations and the laboratory RSV counts seemed to appear in the same week (lag = 0). All other syndromes appeared to be 1–3 weeks later than the RSV counts, except absenteeism, which is 2 weeks earlier. Again, absenteeism seemed to be the earliest syndrome (2–5 weeks earlier than RSV, influenza A, and influenza B), followed by the hospital syndrome (0–2 weeks earlier), the GP-based and prescription-based syndromes (2 weeks earlier until 1 week later), the laboratory submission syndrome (1 week earlier until 2 weeks later), and the mortality syndrome (0–3 weeks later than RSV, influenza A, and influenza B).

**Discussion**

We explored the potential of 6 Dutch medical registries for respiratory syndromic surveillance. Although several other studies also evaluated routine (medical) data for syndromic surveillance purposes (22–27), most evaluated only 1 syndrome and correlated this only to influenza data. An exception is Bourgeois et al. (24), who validated a respiratory syndrome in relation to diagnoses of several respiratory pathogens in a pediatric population, and Cooper et al. (27), who estimated the contribution of specific respiratory pathogens to variations in respiratory syndromes. Both studies concluded that RSV and influenza explain most of the variations in these syndromes, consistent with our findings.

Our study shows that all syndrome data described in this study showed higher levels in winter, which corresponded to the seasonal patterns of RSV, *S. pneumoniae*, and influenza A and B viruses. Linear regression showed that the syndromes can be explained by lagged laboratory counts for respiratory pathogens (up to 86%, highest effect of influenza A, influenza B, and RSV), which indicates their potential usefulness for syndromic surveillance. Timeliness differed, with up to 5 weeks potential gain in early warning by syndromic data, compared with routine laboratory surveillance data.

A limitation of our study is the short duration of our time series, especially for absenteeism and pharmacy data. Therefore, whether our observed associations between syndromes and pathogen counts can be generalized remains unclear.

We relied on laboratory pathogen counts as a proxy for their prevalence and the illness they cause. Changes in test volume over time would result in misclassification bias (as noncausative pathogens will be detected as well). However, such changes are presumably dwarfed by changes during “truly” epidemic elevations of common respiratory pathogens. Additionally, laboratory diagnostics are mostly performed on hospitalized patients, and thus results inadequately reflect activity of pathogens that predominantly cause mild illness.

By adding seasonal terms, we observed that for the absenteeism and, to a lesser extent, the pharmacy registry, the associations between the respiratory syndromes and the pathogen counts might be biased to some extent. For the GP, hospital, laboratory submission, and mortality data,

---

**Table 4. All respiratory pathogen counts included as explanatory variables in the regression models, the Netherlands, 1999–2004**

| Syndrome data | RSV | Influenza | Influenza | *S. pneumoniae* (residual) | RV | PIV | Adenovirus | Enterovirus | Mycoplasma pneumoniae | Bordetella pertussis |
|---------------|-----|-----------|-----------|---------------------------|----|-----|------------|------------|----------------------|---------------------|
| Absenteeism   | 2   | 5         | 4         | 2                         | 4  | 5   | –          | –          | –                    | –                   |
| GP            | –1  | 1         | 2         | –1                        | 1  | 2   | –2         | –3         | –                   | –3                  |
| Pharmacy      | –1  | 0         | 2         | 0                         | 2  | 5   | –2         | –5         | –                   | –3                  |
| Hospitalization | 0   | 2         | 1         | –                         | –2 | 3   | –          | –          | –                   | –                   |
| Laboratory submissions | –2 | 0         | 1         | –3                        | –  | 2   | –          | –3         | –                   | –3                  |
| Mortality     | –3  | 1         | 0         | –                         | –  | –   | –          | –3         | –                   | –3                  |

* *S. pneumoniae, Streptococcus pneumoniae; RSV, respiratory syncytial virus; RV, rhinovirus; PIV, parainfluenza virus; GP, general practice; –, pathogen not included in model.
†The lag time (in weeks) is indicated, that showed optimal fit between syndrome time-series and lagged pathogen counts included in the linear regression model; e.g., according to the model, the trend in hospitalizations precedes the influenza A laboratory counts by 2 weeks.

---

**Table 5. Syndrome variation that can be explained by either the pathogen counts, seasonal terms, or pathogen counts and seasonal terms together**

| Syndrome data | Pathogens, % | Pathogens and seasonal terms, % | Seasonal terms, % |
|---------------|--------------|--------------------------------|-------------------|
| Absenteeism   | 68           | 80                             | 79                |
| GP            | 86           | 89                             | 75                |
| Pharmacy      | 80           | 87                             | 77                |
| Hospitalization | 84       | 88                             | 75                |
| Laboratory submissions | 61        | 63                             | 53                |
| Mortality     | 78           | 78                             | 52                |

*Estimated by 3 different R² values for each registry: 1) for the syndromes explained by pathogen counts alone; 2) after adding seasonal terms to the pathogen model; and 3) for the syndromes explained by seasonal terms alone (sine and cosine parameters). GP, general practice.
The higher \( R^2 \) value of the absenteeism model with seasonal terms alone suggests seasonality of absenteeism caused by several nonrespiratory conditions (28,29). To some extent, this also applies to the pharmacy syndrome, which includes medications that are not specific for respiratory infections (e.g., antimicrobial drugs). This could be validated in future studies by linking medications to illness. However, for both the absenteeism and pharmacy syndromes, the variation explained by seasonal terms is probably overestimated to some extent because data for only 2 and 3 years were used. Consequently, these time series contained less information on variation between different years than for the other registries, which benefits fitting of a model with several sine and cosine terms.

To our knowledge, laboratory submission data (test requests) have not been evaluated before as a data source for syndromic surveillance. The modest explained variance for the laboratory submissions syndrome could possibly reflect the limited use in our country of laboratory testing algorithms, which leads to substantial differences in diagnostic regimes for patients with similar clinical symptoms. In addition, occasional extra alertness by clinicians can make these data unreliable for surveillance. For instance, an unusual peak was observed in the laboratory submissions syndrome in 1999, after the official announcement of an outbreak of Legionnaires’ disease (30).

An unexpected increase was also observed in the absenteeism, GP, and pharmacy syndromes, which occurred consistently each year around October (2001–2004). These peaks preceded the syndrome peaks concurring with peaks in influenza A, influenza B, and RSV counts and may be caused by rhinovirus activity—and asthma exacerbations caused by rhinovirus—which usually rises in the fall (31–33). Rhinovirus might go undetected because GP physicians rarely ask for diagnostics if they suspect a nonbacterial cause for relatively mild respiratory disease. Although

Table 6. Standardized parameter estimates (\( \beta_n \)) for all respiratory pathogen counts included as explanatory variables in the regression models, before and after adding seasonal terms to the models†

| Syndrome data | RSV | Influenza A | Influenza B | S. pneumoniae (residual) | RV | PIV | Adenovirus | Enterovirus | Mycoplasma pneumoniae | Bordetella pertussis |
|---------------|-----|-------------|-------------|-------------------------|----|-----|------------|------------|---------------------|---------------------|
| Absenteeism   | 0.31/NS | 0.27/NS | 0.33/NS | 0.28/NS | 0.19/NS | 0.20/NS | -- | -- | -- | -- |
| GP            | 0.60/NS | 0.32/NS | 0.20/NS | 0.13/NS | 0.07/NS | 0.14/NS | 0.07/NS | -- | 0.06/NS | -- |
| Pharmacy      | 0.51/NS | 0.32/NS | 0.16/NS | 0.10/NS | 0.08/NS | 0.08/NS | 0.08/NS | -- | 0.05/NS | -- |
| Hospitalization | 0.54/NS | 0.22/NS | 0.24/NS | 0.25/NS | 0.16/NS | 0.16/NS | 0.08/NS | -- | 0.12/NS | 0.11/NS |
| Laboratory submissions | 0.44/NS | 0.34/NS | 0.12/NS | 0.13/NS | 0.09/NS | 0.05/NS | -- | -- | -- | -- |
| Mortality     | 0.48/NS | 0.19/NS | 0.22/NS | 0.28/NS | -- | 0.17/NS | -- | 0.10/NS | -- | -- |

†For example, 0.60/0.40 for RSV indicates a standardized \( \beta \) of 0.60 for RSV in the model with only pathogen variables and a \( \beta \) of 0.40 in the same model after adding seasonal terms.

Figure 2. The (maximum) \( R^2 \) by the lagged syndromes with the hospital syndrome as a reference. Aggregated by week, univariate Pearson correlation coefficients were calculated of the hospital syndrome and each of the other syndromes. Note that the Pearson correlation coefficients are calculated over different periods for the different registries because not all registries cover the same period (Table 1). Measured by the syndrome lag with the maximized \( R^2 \), the timeliness differed between the registries in the following order: absenteeism, hospital, pharmacy/general practice (GP), mortality/laboratory submissions (as projected on the x-axis).
specific asthma diagnoses were excluded from the respiratory syndrome definitions, exacerbations of asthma might affect other respiratory categories in the GP or pharmacy syndrome. This observation illustrates that additional diagnostics are needed for identifying the causes of unexplained respiratory disease elevations. Several novel respiratory pathogens for which diagnostics are not yet widely available have been discovered in recent years, underlining that it is quite possible that “hidden” epidemics occur (34–36). The extra October peak and several other syndrome elevations above the 95% UCLs in our study may well reflect such hidden epidemics. The fact that these occur is supported by studies showing that many individual syndrome cases cannot be linked to known pathogens. For example, Cooper et al. (37), who investigated syndromic signals by using patient self-sampling (at home), could only obtain diagnostic results for 22% of these cases.

For early warning surveillance, timeliness is crucial. Absenteeism data seem to have the best timeliness, but their lack of medical detail complicates interpretation. Unexpectedly, the hospital data reflect respiratory pathogen activity earlier than the GP data. Although in the Netherlands patients are encouraged to consult their GP before going to the hospital, elderly persons, for whom respiratory infections are more likely to cause severe illness, may often go to a hospital directly. Therefore, hospital data may prove to be an earlier marker for respiratory disease than GP data, but this possibility needs further exploration.

An important concern when using syndromic surveillance is that it may generate nonspecific alerts, which, if they happen regularly, would lead to lack of confidence in a syndrome-based surveillance system. Here, we see a clear advantage of using data from multiple registries in parallel so that signal detection can be made more specific by focusing on signals that occur concurrently in >1 data source. To illustrate this we defined every exceeding of the UCLs of the regression models as a “signal,” i.e., a syndrome elevation unexplained by known pathogen activity and therefore possibly reflecting activity of underdiagnosed or emerging infectious disease. Over 2002–2003 (the period that all 6 registries were in study), only 5 “concurrent” signals occurred versus 34 “single” signals over all registries. We did not evaluate whether the syndromes indeed detect outbreaks of infectious diseases earlier than clinical or laboratory pathogen surveillance. Such an evaluation is often performed by testing the ability to detect historical natural outbreaks or simulated outbreaks (10,38). However, historical natural outbreaks are rare and simulated outbreaks may be unrealistic. Nevertheless, further research into the outbreak detection performance of these syndromes would be worthwhile.

The results of this study suggest that it might be best to combine syndromic data and pathogen counts in a prospective surveillance system. Such surveillance can identify distinct syndrome elevations that cannot be explained by respiratory pathogen activity as indicated by routine laboratory pathogen surveillance.

Conclusion

Overall, the GP, hospital, mortality and, to a lesser extent, laboratory submission syndromes reflect week-to-week fluctuations in the time-series of respiratory pathogens as detected in the laboratory. Registries monitoring trends of these syndromes will therefore most likely reflect illness caused by emerging or underdiagnosed respiratory pathogens as well and therefore are suited for syndromic surveillance. Further research would be required to assess to what extent absenteeism and pharmacy data reflect respiratory illness. Investigating the actual outbreak detection performance of the syndromes in this study would also be worthwhile.

Data from the registries in this study are not yet real-time available, although given modern information technology, this availability is clearly feasible. Our study can help prioritize which type of healthcare data to include in future syndromic real-time surveillance systems.

Acknowledgments

We thank Daan Notermans for his expert opinion on providing syndrome definitions; Mariken van der Lubben for reading and commenting on the manuscript; Statistics Netherlands (CBS, Ingeborg Deerenberg and John Kartopuwiro), the Foundation for Pharmaceutical Statistics (SFK, Jan-Dirk Kroon and Fabienne Griens), the Dutch National Medical Register (LMR, Willem Hoogen Stoevenbeld), and the National Information Network of GPs (LINH, Robert Verheij) for providing data; and the members of the Dutch Working Group on Clinical Virology for collecting and providing weekly positive diagnostic results.

Mr van den Wijngaard is an epidemiologist at the Center for Infectious Disease Control at the National Institute of Public Health and the Environment (RIVM), Bilthoven. His main research interests include the use of healthcare data for infectious disease surveillance and monitoring.

References

1. Buehler JW, Berkelman RL, Hartley DM, Peters CJ. Syndromic surveillance and bioterrorism-related epidemics. Emerg Infect Dis. 2003;9:1197–204.
2. Lazarus R, Kleinman KP, Dashevsky I, DeMaria A, Platt R. Using automated medical records for rapid identification of illness syndromes (syndromic surveillance): the example of lower respiratory infection. BMC Public Health. 2001;1:9.
3. Fleming DM, Barley MA, Chapman RS. Surveillance of the bioterrorist threat: a primary care response. Commun Dis Public Health. 2004;7:68–72.
4. Miller M, Roche P, Spencer J, Deeble M. Evaluation of Australia’s National Notifiable Disease Surveillance System. Commun Dis Intell. 2004;28:311–23.
Syndromic Surveillance for Respiratory Pathogens

5. Ohkusa Y, Shigematsu M, Taniguchi K, Okabe N. Experimental surveillance using data on sales of over-the-counter medications—Japan, November 2003–April 2004. MMWR Morb Mortal Wkly Rep. 2005;54(Suppl):47–52.

6. Heffernan R, Mostashari F, Das D, Karpati A, Kuldoff M, Weiss D. Syndromic surveillance in public health practice, New York City. Emerg Infect Dis. 2004;10:858–64.

7. Mostashari F, Fine A, Das D, Adams J, Layton M. Use of ambulance dispatch data as an early warning system for community-wide influenza-like illness, New York City. J Urban Health. 2003;80:143–9.

8. Rozt LD, Khan AS, Lillibrige SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002;8:225–30.

9. Lazarus R, Kleinman K, Dasheisky I, Adams C, Klad P, DeMaria A Jr, et al. Use of automated ambulatory-care encounter records for detection of acute illness clusters, including potential bioterrorism events. Emerg Infect Dis. 2002;8:753–60.

10. Buckeridge DL. Outbreak detection through automated surveillance: a review of the determinants of detection. J Biomed Inform. 2007;40:370–9.

11. Heijnen ML, Dorigo-Zetsma JW, Bartelds AI, Wilbrink B, Sprenger ML, et al. Syndromic surveillance for respiratory pathogens and influenza-like illnesses in general practices—the Netherlands, winter 1997–98. Euro Surveill. 1999;4:81–4.

12. Hertzberger LI, Huisman J, Witterdink JB. The global eradication of polio by the year 2000 [in Dutch]. Ned Tijdschr Geneeskd. 1998;142:972–3.

13. Widdowson MA, Bosman A, van Straten E, Tinga M, Chaves S, van Eeren L, et al. Automated, laboratory-based system using the Internet for disease outbreak detection, the Netherlands. Emerg Infect Dis. 2003;9:1046–9.

14. Van den Brandhof WE, Kroeys ACM, Bosman A, Peeters MF, Heijnen MLA. Reporting virus diagnostics in the Netherlands: representativeness of the virological weekly reports [in Dutch]. Infectieziekten Bulletin. 2002;13:110–3 [cited 2008 Apr 8]. Available from http://www.rivm.nl/infectieziektenbulletin/bul1304/vir_diagnostiek.html

15. Akaike H. A new look at statistical model identification. IEEE Trans-actions on Automatic Control. 1974;19:716–23.

16. Avadhanaula V, Rodriguez CA, Devincezenzo JP, Wang Y, Webby RJ, Ulett GC, et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species– and cell type–dependent manner. J Virol. 2006;80:1629–36.

17. Hament JM, Aerts PC, Fleer A, Van Dijk H, Harmsen T, Kimpen JL, et al. Enhanced adherence of Streptococcus pneumoniae to human epithelial cells infected with respiratory syncytial virus. Pediatr Res. 2004;55:972–8.

18. Kim PE, Mushar DM, Glezen WP, Rodriguez-Barradas MC, Nahm WK, Wright CE. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis. 1996;22:100–6.

19. Hament JM, Kimpen JL, Fleer A, Wolfis TF. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol. 1999;26:189–95.

20. Heisterkamp SH, Dekkers ALM, Heijne JC. Automated detection of infectious disease outbreaks: hierarchical time series models. Stat Med. 2006;25:4179–96.

21. Dekkers ALM, Heisterkamp SH. NPBats, Bayesian statistical instrument for trend detection and time-series modelling [in Dutch]. National Institute for Public Health and the Environment (RIVM), 2004; internal report 550002006 [cited 2008 Apr 15]. Available from http://www.rivm.nl/bibliotheek/rapporten/550002006.pdf

22. Miller B, Kassenborgh H, Dunsmaur W, Griffith J, Hadidi M, Nordin JD, et al. Syndromic surveillance for influenza-like illness in ambulatory care network. Emerg Infect Dis. 2004;10:1806–11.

23. Brillman JC, Burr T, Forslund D, Joyce E, Picard R, Umland ET. Modeling emergency department visit patterns for infectious disease complaints: results and application to disease surveillance. BMC Med Inform Decis Mak. 2005;5:4.

24. Bourgeois FT, Olson KL, Brownstein JS, McAdam AJ, Small K. Validation of syndromic surveillance for respiratory infections. Ann Emerg Med. 2006;47:265.e1–e3.

25. Smith G, Hippsle-Cox J, Harcourt S, Heaps M, Painter M, Potter A, et al. Developing a national primary care-based early warning system for health protection—a surveillance tool for the future? Analysis of routinely collected data. J Public Health (Oxf). 2007;29:75–82.

26. Verga E, Grais RF, Sarter H, Faget JP, Lambert B, Valleron AJ, et al. Medication sales and syndromic surveillance, France. Emerg Infect Dis. 2006;12:416–21.

27. Cooper DL, Smith GE, Edmonds WJ, Joseph C, Gerard E, George RC. The contribution of respiratory pathogens to the seasonality of NHS Direct calls. J Infect. 2007;55:240–8.

28. Fisman DN. Seasonality of infectious diseases. Annu Rev Public Health. 2007;28:127–43.

29. van Rossum CT, Shipley MJ, Hemingway H, Grobbbee DE, Mackenbach JP, Marmot MG. Seasonal variation in cause-specific mortality: are there high-risk groups? 25-year follow-up of civil servants from the first Whitehall study. Int J Epidemiol. 2001;30:1109–16.

30. Den Boer JW, Yzerman EP, Schellekens J, Lettinga KD, Boshuizen HC, Van Steenbergen JE, et al. A large outbreak of Legionnaires' disease at a flower show, the Netherlands, 1999. Emerg Infect Dis. 2002;8:37–43.

31. Gwatney JM Jr, Hendley JO, Simon G, Jordan WS Jr. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966;275:1261–8.

32. Dales RE, Schweitzer I, Toogood JH, Drouin M, Yang W, Dolovich J, et al. Respiratory infections and the autumn increase in asthma morbidity. Eur Respir J. 1996;9:72–79.

33. Van Gageldonk-Lafeber AB, Heijnen ML, Bartelds AI, Peters MF, van der Plas SM, Wilbrink B. A case-control study of acute respiratory tract infection in general practice patients in the Netherlands. Clin Infect Dis. 2005;41:490–7.

34. Allander T, Tammi MT, Erikkson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–6.

35. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. Nature. 2003;423:139–44.

36. Van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout BJ, Wolthers KC, et al. Identification of a new human coronavirus. Nat Med. 2004;10:368–73.

37. Cooper DL, Smith GE, Chimnana F, Joseph C, Loveridge P, Sebastianpillai P, et al. Linking syndromic surveillance with virological self-sampling. Epidemiol Infect. 2008;136:222–4.

38. Bravata DM, McDonald KM, Smith WM, Rydzak C, Szeto H, Buckeridge DL, et al. Systematic review: surveillance systems for early detection of bioterrorism-related diseases. Ann Intern Med. 2004;140:910–22.

Address for correspondence: Cees van den Wijngaard, Centre for Infectious Disease Control, Netherlands National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, the Netherlands; email: cees.van.den.wijngaard@rivm.nl

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.
Validation of Syndromic Surveillance for Respiratory Pathogen Activity

Technical Appendix

Detailed Syndrome Definitions for Each Syndrome Data Source

A general respiratory syndrome was defined for each data source (except for the absenteeism data, which contain no medical information; see Table 1). We used the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes as selected by the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA (www.bt.cdc.gov/surveillance/syndromedef). To define a respiratory syndrome, we selected both the codes for general respiratory symptoms and diagnoses (category 1 in CDC list) and the codes for specific respiratory biologic agent diagnoses (category 3 in CDC list). For the hospital data (see Table 1), we used these syndrome codes with some minor adaptations for the Dutch version of ICD-9-CM. For the mortality data (see Table 2) the ICD-9-CM codes were converted into ICD 10th revision (ICD-10) codes by using the World Health Organization ICD-9/ICD-10 translation list and expert opinion, if necessary (ICD-9/ICD-10 Translator; see www.who.int/classifications/en). For the GP consultation data (see Table 3), International Classification of Primary Care (ICPC) codes were included in a respiratory syndrome by expert opinion, guided by the CDC respiratory syndrome case definition.

For a respiratory syndrome definition based on the pharmacy data, we used Anatomical Therapeutic Chemical Classification System (ATC) codes of medications that experts considered indicative for respiratory infectious disease complaints. Of those, we included only ATC-5 codes that had higher levels in winter. See Table 4 for the specific included ATC-5 codes.

For a respiratory syndrome definition based on the laboratory submissions data, we included all submissions for specific diagnostics that are known to be of respiratory cause: 1) all submissions for microbiologic diagnostic tests on respiratory materials (sputum, bronchoalveolar lavage, pleural liquid); 2) all submissions for serology on known specific respiratory pathogens
(see list of serologic tests in Table 5); 3) all submissions for *Legionella* spp. or *Streptococcus pneumoniae* antigen tests on urine.

For all data types we assumed that in a prospective setting real-time syndrome-classification would be feasible (on date of consultation/hospitalization/death/submission/dispense).

| ICD-9-CM code | Description                                   |
|---------------|-----------------------------------------------|
| 020.3         | Primary pneumonic plague                      |
| 020.4         | Secondary pneumonic plague                    |
| 020.5         | Pneumonic plague not otherwise specified      |
| 021.2         | Pulmonary tularemia                           |
| 022.1         | Pulmonary anthrax                             |
| 031.0         | Mycobacteria, pulmonary                       |
| 031.8         | Other specified mycobacterial diseases        |
| 031.9         | Mycobacteria diseases/unspecified             |
| 032.0         | Faucial diphtheria                            |
| 032.1         | Nasopharynx diphtheria                        |
| 032.2         | Anterior nasal diphtheria                     |
| 032.3         | Laryngeal diphtheria                          |
| 032.89        | Diphtheria not elsewhere classified           |
| 032.9         | Diphtheria not otherwise specified            |
| 033.0         | *Bordetella pertussis*                        |
| 033.1         | *Bordetella parapertussis*                    |
| 033.8         | Whooping cough not elsewhere classified       |
| 033.9         | Whooping cough (unspecified organism)         |
| 034.0         | Streptococcal sore throat                     |
| 055.1         | Postmeasles pneumonia                         |
| 055.2         | Postmeasles otitis media                      |
| 073.0         | Ornithosis, with pneumonia                    |
| 073.7         | Ornithosis, with other specified complication |
| 073.8         | Ornithosis, with unspecified complication     |
| 073.9         | Ornithosis, unspecified                       |
| 079.0         | Adenovirus infection not otherwise specified  |
| 079.1         | Echovirus infection not otherwise specified nos.|
| 079.2         | Coxsackie virus                               |
| 079.3         | Rhinovirus infection not otherwise specified  |
| 079.8         | Viral infection in conditions classified else where and of unspecified site |
| 098.6         | Gonococcal, infection of pharynx              |
| 114.0         | Primary coccidioidomycosis (lung)             |
| Code  | Diagnosis                                      |
|-------|-----------------------------------------------|
| 114.5 | Pulmonary coccidioidomycosis, unspecified     |
| 114.9 | Coccidioidomycosis not otherwise specified   |
| 115.00| Histoplasmosis, without mention of manifestation |
| 115.05| *Histoplasma capsulatum* pneumonia            |
| 115.09| *Histoplasma capsulatum* not elsewhere classified |
| 115.10| *Histoplasma duboisii* not otherwise specified |
| 115.15| *Histoplasma duboisii* pneumonia              |
| 115.90| Histoplasmosis, without manifestation        |
| 115.95| Histoplasmosis pneumonia                     |
| 115.99| Histoplasmosis not elsewhere classified       |
| 116.0 | Blastomycosis                                 |
| 116.1 | Paracoccidioidomycosis                       |
| 117.1 | Sporotrichosis                                |
| 117.3 | Pulmonary aspergillosis                       |
| 117.5 | Cryptococcosis                                |
| 130.4 | *Toxoplasma* pneumonitis                     |
| 136.3 | Pneumocystosis                                |
| 460   | Nasopharyngitis, acute                        |
| 462   | Pharyngitis, acute not otherwise specified    |
| 463   | Tonsillitis, acute                            |
| 464.0 | Acute laryngitis                              |
| 464.10| Tracheitis without obstruction                |
| 464.11| Acute tracheitis with obstruction             |
| 464.20| Laryngotracheitis without obstruction         |
| 464.21| Acute laryngotracheitis with obstruction      |
| 464.30| Epiglottitis acute without obstruction        |
| 464.31| Acute epiglottitis with obstruction           |
| 464.4 | Croup                                         |
| 465.0 | Laryngopharyngitis, acute                    |
| 465.8 | Upper respiratory infection, other multiple sites |
| 465.9 | Upper respiratory infection, acute not otherwise specified |
| 466.0 | Bronchitis acute                              |
| 466.1 | Acute bronchiolitis                          |
| 478.9 | Respiratory tract disease                    |
| 480.0 | Adenoviral pneumonia                         |
| 480.1 | Pneumonia due to respiratory syncytial virus |
| 480.2 | Parainfluenza viral pneumonia                |
| 480.8 | Viral pneumonia not elsewhere classified      |
| 480.9 | Pneumonia, viral                              |
| 481   | Pneumococcal pneumonia (lobar)               |
| 482.0 | Pneumonia due to *Klebsiella pneumoniae*     |
| 482.1 | Pneumonia due to *Pseudomonas*               |
| 482.2 | *Haemophilus influenzae* pneumonia           |
| 482.3 | Pneumonia due to *Streptococcus*             |
482.4  Pneumonia due to *Staphylococcus*
482.8  Pneumonia due to bacteria not elsewhere classified
482.9  Pneumonia due to bacteria not otherwise specified
483    Pneumonia due to organism not elsewhere classified
484.1  Pneumonia due to cytomegalic inclusion disease
484.3  Pneumonia in whooping cough
484.5  Pneumonia in anthrax
484.6  Pneumonia in aspergillosis
484.7  Pneumonia in other systemic mycoses
484.8  Pneumonia in infection disease not elsewhere classified
485    Bronchopneumonia organism unspecified
486    Pneumonia, organism not otherwise specified
487.0  Influenza with pneumonia
487.1  Influenza with other respiratory manifestations
487.8  Influenza with other manifestations
489    Bronchitis not otherwise specified
511.0  Pleurisy without mention of effusion or current tuberculosis
511.1  Pleurisy with effusion, with mention of a bacterial cause other than tuberculosis
511.8  Hemothorax
513.0  Abscess lung
513.1  Abscess of mediastinum
513.4  Edema lung acute not otherwise specified
518.8  Other diseases of lung not otherwise classified
519.2  Mediastinitis
519.3  Mediastinum, diseases not elsewhere classified
769  Respiratory distress syndrome
786.00 Respiratory abnormality
786.09 Other specified respiratory abnormality
786.1  Stridor
786.2  Cough
786.3  Hemoptysis
786.52 Painful respiration/pleurodynia
799.1  Respiratory arrest

*ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification.

Table 2. ICD-10 codes for the respiratory syndrome in mortality data*

| ICD-10 code | Description                                |
|-------------|--------------------------------------------|
| A202        | Pneumonic plague                           |
| A212        | Pulmonary tularemia                        |
| A221        | Pulmonary anthrax                          |
| A310        | Pulmonary mycobacterial infection          |
| A318        | Other mycobacterial infections             |
| A319        | Mycobacterial infection, unspecified       |
| A360        | Pharyngeal diphtheria                      |

*ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification.
| Code  | Diagnosis                                      |
|-------|------------------------------------------------|
| A361  | Nasopharyngeal diphtheria                      |
| A362  | Laryngeal diphtheria                           |
| A368  | Other diphtheria                               |
| A369  | Diphtheria, unspecified                        |
| A370  | Whooping cough due to *Bordetella pertussis*    |
| A371  | Whooping cough due to *Bordetella parapertussis*|
| A378  | Whooping cough due to other *Bordetella* species|
| A379  | Whooping cough, unspecified                    |
| A481  | Legionnaires' disease                          |
| A545  | Gonococcal pharyngitis                         |
| A70   | *Chlamydia psittaci* infection                 |
| B012  | Varicella pneumonia (J17.1*)                   |
| B052  | Measles complicated by pneumonia (J17.1*)       |
| B053  | Measles complicated by otitis media (H67.1*)   |
| B340  | Adenovirus infection, unspecified              |
| B341  | Enterovirus infection, unspecified             |
| B342  | Coronavirus infection, unspecified             |
| B348  | Other viral infections of unspecified site     |
| B380  | Acute pulmonary coccidioidomycosis             |
| B382  | Pulmonary coccidioidomycosis, unspecified      |
| B389  | Coccidioidomycosis, unspecified               |
| B390  | Acute pulmonary histoplasmosis capsulatum      |
| B392  | Pulmonary histoplasmosis capsulatum, unspecified|
| B393  | Disseminated histoplasmosis capsulatum         |
| B394  | Histoplasmosis capsulatum, unspecified         |
| B395  | Histoplasmosis duboisii                        |
| B399  | Histoplasmosis, unspecified                    |
| B400  | Acute pulmonary blastomycosis                 |
| B402  | Pulmonary blastomycosis, unspecified           |
| B407  | Disseminated blastomycosis                    |
| B408  | Other forms of blastomycosis                  |
| B409  | Blastomycosis, unspecified                    |
| B410  | Pulmonary paracoccidioidomycosis              |
| B417  | Disseminated paracoccidioidomycosis           |
| B418  | Other forms of paracoccidioidomycosis          |
| B419  | Paracoccidioidomycosis, unspecified            |
| B420  | Pulmonary sporotrichosis (J99.8*)              |
| B427  | Disseminated sporotrichosis                   |
| B428  | Other forms of sporotrichosis                 |
| B429  | Sporotrichosis, unspecified                   |
| B440  | Invasive pulmonary aspergillosis              |
| B441  | Other pulmonary aspergillosis                 |
| B442  | Tonsillar aspergillosis                       |
| B447  | Disseminated aspergillosis                    |
| Code   | Description                                                                 |
|--------|-----------------------------------------------------------------------------|
| B448   | Other forms of aspergillosis                                                 |
| B449   | Aspergillosis, unspecified                                                  |
| B450   | Pulmonary cryptococcosis                                                    |
| B457   | Disseminated cryptococcosis                                                 |
| B458   | Other forms of cryptococcosis                                               |
| B459   | Cryptococcosis, unspecified                                                 |
| B583   | Pulmonary toxoplasmosis (J17.3*)                                            |
| B59    | Pneumocystosis                                                             |
| B970   | Adenovirus as the cause of diseases classified to other chapters            |
| B971   | Enterovirus as the cause of diseases classified to other chapters           |
| B972   | Coronavirus as the cause of diseases classified to other chapters           |
| B974   | Respiratory syncytial virus as the cause of diseases classified to other chapters |
| B978   | Other viral agents as the cause of diseases classified to other chapters    |
| G473   | Sleep apnea                                                                |
| J00    | Acute nasopharyngitis (common cold)                                        |
| J020   | Streptococcal pharyngitis                                                  |
| J028   | Acute pharyngitis due to other specified organisms                          |
| J029   | Acute pharyngitis, unspecified                                              |
| J030   | Streptococcal tonsillitis                                                   |
| J038   | Acute tonsillitis due to other specified organisms                          |
| J039   | Acute tonsillitis, unspecified                                               |
| J040   | Acute laryngitis                                                           |
| J041   | Acute tracheitis                                                           |
| J042   | Acute laryngotracheitis                                                    |
| J050   | Acute obstructive laryngitis (croup)                                       |
| J051   | Acute epiglottitis                                                         |
| J060   | Acute laryngopharyngitis                                                   |
| J068   | Other acute upper respiratory infections of multiple sites                  |
| J069   | Acute upper respiratory infection, unspecified                              |
| J100   | Influenza with pneumonia, influenza virus identified                        |
| J101   | Influenza with other respiratory manifestations, influenza virus identified  |
| J108   | Influenza with other manifestations, influenza virus identified              |
| J110   | Influenza with pneumonia, virus not identified                              |
| J111   | Influenza with other respiratory manifestations, virus not identified        |
| J118   | Influenza with other manifestations, virus not identified                    |
| J120   | Adenoviral pneumonia                                                       |
| J121   | Respiratory syncytial virus pneumonia                                       |
| J122   | Parainfluenza virus pneumonia                                               |
| J128   | Other viral pneumonia                                                      |
| J129   | Viral pneumonia, unspecified                                                |
| J13    | Pneumonia due to Streptococcus pneumoniae                                  |
| J14    | Pneumonia due to Haemophilus influenzae                                     |
| J150   | Pneumonia due to Klebsiella pneumoniae                                      |
| J151   | Pneumonia due to Pseudomonas                                                |
| Code | Description |
|------|-------------|
| J152 | Pneumonia due to Staphylococcus |
| J153 | Pneumonia due to Streptococcus, group B |
| J154 | Pneumonia due to other streptococci |
| J155 | Pneumonia due to Escherichia coli |
| J156 | Pneumonia due to other aerobic Gram-negative bacteria |
| J157 | Pneumonia due to Mycoplasma pneumoniae |
| J158 | Other bacterial pneumonia |
| J159 | Bacterial pneumonia, unspecified |
| J160 | Chlamydial pneumonia |
| J168 | Pneumonia due to other specified infectious organisms |
| J170 | Pneumonia in bacterial diseases classified elsewhere |
| J171 | Pneumonia in viral diseases classified elsewhere |
| J172 | Pneumonia in mycoses |
| J173 | Pneumonia in parasitic diseases |
| J178 | Pneumonia in other diseases classified elsewhere |
| J180 | Bronchopneumonia, unspecified |
| J182 | Hypostatic pneumonia, unspecified |
| J188 | Other pneumonia, organism unspecified |
| J189 | Pneumonia, unspecified |
| J200 | Acute bronchitis due to Mycoplasma pneumoniae |
| J201 | Acute bronchitis due to Haemophilus influenzae |
| J202 | Acute bronchitis due to streptococcus |
| J203 | Acute bronchitis due to coxsackievirus |
| J204 | Acute bronchitis due to parainfluenza virus |
| J205 | Acute bronchitis due to respiratory syncytial virus |
| J206 | Acute bronchitis due to rhinovirus |
| J207 | Acute bronchitis due to echovirus |
| J208 | Acute bronchitis due to other specified organisms |
| J209 | Acute bronchitis, unspecified |
| J210 | Acute bronchiolitis due to respiratory syncytial virus |
| J218 | Acute bronchiolitis due to other specified organisms |
| J219 | Acute bronchiolitis, unspecified |
| J22 | Unspecified acute lower respiratory infection |
| J398 | Other specified diseases of upper respiratory tract |
| J40 | Bronchitis, not specified as acute or chronic |
| J850 | Gangrene and necrosis of lung |
| J851 | Abscess of lung with pneumonia |
| J852 | Abscess of lung without pneumonia |
| J853 | Abscess of mediastinum |
| J942 | Hemothorax |
| J949 | Pleural condition, unspecified |
| J960 | Acute respiratory failure |
| J969 | Respiratory failure, unspecified |
| J985 | Diseases of mediastinum, not elsewhere classified |
| ICPC codes | Description                                      |
|------------|--------------------------------------------------|
| J998       | Respiratory disorders in other diseases classified elsewhere |
| P220       | Respiratory distress syndrome of newborn          |
| R042       | Hemoptysis                                       |
| R049       | Hemorrhage from respiratory passages, unspecified |
| R05        | Cough                                            |
| R061       | Stridor                                          |
| R063       | Periodic breathing                               |
| R064       | Hyperventilation                                 |
| R065       | Mouth breathing                                  |
| R068       | Other and unspecified abnormalities of breathing  |
| R071       | Chest pain on breathing                          |
| R091       | Pleurisy                                         |
| R092       | Respiratory arrest                               |

*ICD-10, International Classification of Diseases, 10th Revision.*

Table 3. ICPC codes for the respiratory syndrome in general practice consultations data*

| ICPC codes | Description                                      |
|------------|--------------------------------------------------|
| H71        | Acute otitis media/myringitis                    |
| L04        | Chest symptom/complaint                         |
| R01        | Pain respiratory system                         |
| R02        | Shortness of breath/dyspnea                      |
| R03        | Wheezing                                         |
| R04        | Breathing problem, other                         |
| R05        | Cough                                            |
| R07        | Sneezing/nasal congestion                        |
| R21        | Throat symptom/complaint                         |
| R24        | Hemoptysis                                       |
| R29        | Respiratory symptom/complaint, other             |
| R71        | Whooping cough                                   |
| R74        | Upper respiratory infection, acute               |
| R75        | Sinusitis acute/chronic                          |
| R76        | Tonsillitis, acute                               |
| R77        | Laryngitis/tracheitis acute                      |
| R78        | Acute bronchitis/bronchiolitis                   |
| R80        | Influenza                                        |
| R81        | Pneumonia                                        |
| R82        | Pleurisy/pleural effusion                        |
| R83        | Respiratory infection, other                     |
| R93        | Pleural effusion not otherwise specified         |
| R99        | Respiratory disease, other                       |

*ICPC, International Classification of Primary Care.*
Table 4. ATC level 5 codes for the respiratory syndrome in pharmacy data*

| ATC-5 code | Description |
|------------|-------------|
| J01AA      | Tetracyclines |
| J01CA      | Penicillins with extended spectrum |
| J01CR      | Combinations of penicillins, including β-lactamase inhibitors |
| J01FA      | Macrolides |
| R05CA      | Expectorants |
| R05DA      | Opium alkaloids and derivatives |
| R06AD      | Phenothiazine derivatives |

*ATC, Anatomical Therapeutic Chemical Classification System.

Table 5. Serologic test subjects included in the respiratory syndrome for laboratory submissions (see information on other included tests in text)

| Serologic tests performed on                      |
|---------------------------------------------------|
| Adenovirus 2                                      |
| Adenovirus                                        |
| Antibodies to adenovirus                          |
| Antibodies to Aspergillus fumigatus               |
| Antibodies to Aspergillus species                 |
| Antibodies to Chlamydia pneumoniae                |
| Antibodies to Chlamydia psittaci                  |
| Antibodies to Chlamydia species                   |
| Antibodies to coronavirus                         |
| Antibodies to Corynebacterium diphtheriae         |
| Antibodies to influenza A virus                   |
| Antibodies to influenza B virus                   |
| Antibodies to Legionella                          |
| Antibodies to Legionella pneumophila              |
| Antibodies to Legionella pneumophila serogroup 1 |
| Antibodies to Mycoplasma pneumoniae               |
| Antibodies to parainfluenza 1 virus               |
| Antibodies to parainfluenza 2 virus               |
| Antibodies to parainfluenza 3 virus               |
| Antibodies to parainfluenza virus                 |
| Antibodies to respiratory syncytial virus        |
| Antibodies to Streptococcus pneumoniae            |
| Antigen Aspergillus fumigatus                     |
| Antigen Aspergillus species                       |
| IgA Chlamydia pneumoniae                          |
| IgA Chlamydia species                             |
| IgA Mycoplasma pneumoniae                         |
| IgG adenovirus                                    |
| IgG Leptospira                                    |
| IgG Aspergillus fumigatus                         |
| IgG Chlamydia pneumoniae                          |
| IgG Chlamydia psittaci                            |
| IgG Chlamydia species                             |
| IgG influenza virus A                              |
Details on the Regression Model Variables

We constructed a multiple linear regression model:

\[ S_t = b_0 + b_1 P_{A,t+x} + b_2 P_{B,t+y} + \ldots + R_t \]

\( S \) = level of a respiratory syndrome

\( t \) = time in weeks

\( P_{A/B/etc} \) = lagged respiratory pathogens detected in the laboratory

\( x/y/etc \) = lag time in weeks, for shifting the pathogen time series over a range of -5 up to +5 weeks.

\( R \) = residual of the model

A forward stepwise regression approach was used, each step selecting the lagged pathogen that contributed most to the model fit (assessed with Akaike’s information criterion). Each pathogen was included in the model only once and only if it contributed significantly (\( p < 0.05 \)). Negative associations were excluded to avoid biologically implausible associations in the models between
the pathogens and the syndromes (e.g., negative associations between enteroviruses, which peak in summer, and respiratory syndromes, which peak in winter). We checked for significant autocorrelation in the residual of the models.

To investigate whether seasonal variation could be a confounder for the association between pathogens and syndromes we then calculated 3 $R^2$ values for the models: 1) with only pathogen variables, 2) after adding seasonal terms ($\text{sine}(k \pi \text{week}/52)$ and $\text{cosine}(k \pi \text{week}/52)$, $k = 1, 2, 3$), and 3) with only seasonal terms. We calculated the standardized parameter estimates as well, before and after adding seasonal terms. The standardized parameter estimates are the beta values that result when all variables are standardized to a mean of 0 and a variance of 1. These estimates are computed by multiplying the original estimates by the standard deviation of the regressor (independent) variable and then dividing by the standard deviation of the dependent variable.